Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma

Neuro-oncology
Melissa M SinghJoya Chandra

Abstract

Glioblastoma (GBM) is the most common and aggressive form of brain cancer. Our previous studies demonstrated that combined inhibition of HDAC and KDM1A increases apoptotic cell death in vitro. However, whether this combination also increases death of the glioma stem cell (GSC) population or has an effect in vivo is yet to be determined. Therefore, we evaluated the translational potential of combined HDAC and KDM1A inhibition on patient-derived GSCs and xenograft GBM mouse models. We also investigated the changes in transcriptional programing induced by the combination in an effort to understand the induced molecular mechanisms of GBM cell death. Patient-derived GSCs were treated with the combination of vorinostat, a pan-HDAC inhibitor, and tranylcypromine, a KDM1A inhibitor, and viability was measured. To characterize transcriptional profiles associated with cell death, we used RNA-Seq and validated gene changes by RT-qPCR and protein expression via Western blot. Apoptosis was measured using DNA fragmentation assays. Orthotopic xenograft studies were conducted to evaluate the effects of the combination on tumorigenesis and to validate gene changes in vivo. The combination of vorinostat and tranylcypromine reduced GSC viability ...Continue Reading

References

Nov 6, 1998·The Journal of Experimental Medicine·V De LaurenziG Melino
Jul 7, 1999·Journal of the National Cancer Institute·A TannapfelC Wittekind
Dec 14, 1999·The Journal of Biological Chemistry·M Oren
Feb 5, 2000·Journal of Neurosurgery·S LalF F Lang
May 19, 2001·European Journal of Biochemistry·E Appella, C W Anderson
Dec 26, 2001·Cell Death and Differentiation·T J GrobA Tobler
Jan 10, 2002·Cell·C Prives, J L Manley
Feb 15, 2002·The Journal of Biological Chemistry·Thorsten StieweBrigitte M Pützer
Feb 23, 2002·Cell Death and Differentiation·I CascianoM Romani
Sep 18, 2002·The Journal of Experimental Medicine·Alex I ZaikaUte M Moll
Oct 1, 2003·Molecular and Cellular Biology·Stefanie GalbánMyriam Gorospe
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dong YinH Phillip Koeffler
Mar 18, 2008·Trends in Biochemical Sciences·Federico FornerisAndrea Mattevi
Apr 30, 2008·Advances in Experimental Medicine and Biology·Kageaki Kuribayashi, Wafik S El-Deiry
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 23, 2008·Genes & Development·Richard TomasiniTak W Mak
May 24, 2011·Nature Cell Biology·Antonio AdamoJuan Carlos Izpisua Belmonte
Jul 19, 2011·Journal of Biomedicine & Biotechnology·Claudia P MillerJoya Chandra
Apr 18, 2012·Molecular and Cellular Biology·Wensheng YanXinbin Chen

❮ Previous
Next ❯

Citations

Jan 23, 2016·Molecular Oncology·Rikke D RasmussenPetra Hamerlik
Dec 10, 2015·Epigenomics·Xueshun WangPeng Zhan
Oct 24, 2015·The International Journal of Biochemistry & Cell Biology·Rosaria BenedettiLucia Altucci
Aug 2, 2016·Epigenomics·Alba Maiques-Diaz, Tim Cp Somervaille
Sep 3, 2016·Epigenomics·Wallax Augusto Silva FerreiraBárbara do Nascimento Borges
Oct 19, 2016·Clinical Epigenetics·Angel R de Lera, A Ganesan
Apr 2, 2016·Science Advances·Rishi R LullaRintaro Hashizume
Feb 1, 2018·Cell Biology and Toxicology·Yoichiro KawamuraKinichi Nakashima
Nov 23, 2019·International Journal of Cancer. Journal International Du Cancer·Tinka HaydnSimone Fulda
Jul 18, 2020·Neuro-oncology·Theodore P Nicolaides, Rintaro Hashizume
Nov 24, 2019·Cancers·Panagiotis KarakaidosAngeliki Magklara
Jul 9, 2020·Cancer Chemotherapy and Pharmacology·R Gajendra ReddyArvind Kumar
Sep 20, 2018·Cell Communication and Signaling : CCS·Keri CallegariVidya Gopalakrishnan
Sep 12, 2018·Cancers·Ying ZhangRoger Abounader
May 17, 2019·Indian Journal of Clinical Biochemistry : IJCB·Aman KumarRajendra Prasad
Feb 25, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Magimairajan Issai VananDavid D Eisenstat
Apr 4, 2019·International Journal of Molecular Sciences·Wenbo Li, Zheng Sun
Jun 4, 2020·Cell Death & Disease·Jaione Auzmendi-IriarteAnder Matheu
Jun 26, 2020·Journal of Neuro-oncology·Kevin SheeGregory J Tsongalis
Jul 20, 2020·Journal of Experimental & Clinical Cancer Research : CR·Rui ChenYali Wang
Dec 29, 2020·Bioorganic & Medicinal Chemistry Letters·M Naveen SadhuSridharan Rajagopal
Dec 22, 2020·Frontiers in Oncology·Luis M Valor, Irati Hervás-Corpión
Nov 5, 2020·Pharmacology & Therapeutics·Elena KunadisChristina Piperi
Mar 7, 2021·Cancers·Hong-My NguyenDipongkor Saha
May 10, 2021·Bioorganic Chemistry·Xiuhong WeiFengyuan Che
Jun 10, 2021·European Journal of Medicinal Chemistry·Ying-Chao DuanYuan-Yuan Guan
Jul 3, 2021·Cancers·Javier Martinez-UserosJesus Garcia-Foncillas
Aug 28, 2021·Frontiers in Cell and Developmental Biology·Virginia LópezMario F Fraga
Sep 8, 2015·Epigenomics·Wenji YanMingzhou Guo
Nov 4, 2021·Drug Discovery Today·Yihui SongBin Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis